Cite
HARVARD Citation
Jabbour, E. et al. (2020). Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet. 7 (7), pp. e523-e533. [Online].